Kristin Risa

发表

Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Ø. Fluge, O. Mella, A. de Vries, 2019, Clinical therapeutics.

Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome.

Ø. Fluge, O. Bruland, P. Ueland, 2016, JCI insight.

Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome

Ø. Fluge, O. Bruland, O. Mella, 2016, PloS one.

Identification of Dynamic Changes in Proteins Associated with the Cellular Cytoskeleton after Exposure to Okadaic Acid

P. Roepstorff, T. Solstad, J. A. Opsahl, 2013, Marine drugs.

A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome

Ø. Fluge, A. Fosså, K. Tronstad, 2021, JCI Insight.

Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study

B. Lie, Ø. Fluge, A. Fosså, 2020, Frontiers in Medicine.

Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study

Ø. Fluge, O. Bruland, H. Næss, 2011, PloS one.

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment

Ø. Fluge, O. Bruland, O. Mella, 2015, PloS one.

B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

O. Bruland, O. Mella, P. Borchgrevink, 2019, Annals of Internal Medicine.

Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients

Ø. Fluge, O. Bruland, K. Tronstad, 2022, PLoS ONE.